SIC
BEAM icon

SJS Investment Consulting’s Beam Therapeutics BEAM Stock Holding History

SJS Investment Consulting’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72 Hold
3
– – ﹤0.01% 2190
2025
Q4 		$84 Buy
+3
New +$77 ﹤0.01% 1964
2025
Q2 		– Sell
-5
Closed -$98 – 1567
2025
Q1 		$98 Hold
5
– – ﹤0.01% 1523
2024
Q4 		$124 Buy
5
+3
+150% +$77 ﹤0.01% 1507
2024
Q3 		$49 Hold
2
– – ﹤0.01% 1621
2024
Q2 		$47 Buy
+2
New +$49 ﹤0.01% 1623

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SJS Investment Consulting's BEAM Position: Q1 2026 in Review

SJS Investment Consulting held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 3 shares worth $72. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

SJS Investment Consulting first reported a position in BEAM in Q2 2024 and has held it in 6 quarters since. The position peaked at $124 in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • SJS Investment Consulting held 3 shares of Beam Therapeutics worth $72 as of Q1 2026.
  • SJS Investment Consulting left its Beam Therapeutics share count unchanged in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2026, its #2190 holding.
  • SJS Investment Consulting first reported a position in Beam Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • SJS Investment Consulting's Beam Therapeutics position peaked at $124 in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on SJS Investment Consulting's 13F filing for Q1 2026, filed 23 Apr 2026.